

---

primary studies - published RCT

## Randomized trial of efficacy and safety of dornase alfa delivered by eRapid nebulizer in cystic fibrosis patients

**Code:** PM25921451

**Year:** 2015 **Date:** 2015

**Author:** Sawicki GS

### Study design (if review, criteria of inclusion for studies)

Randomized crossover study

### Participants

87 CF patients ( $\geq 6$  years)

### Interventions

dornase alfa 2.5mg/d in 2-week periods with the Pari eRapid and Pari LC Plus jet nebulizers.

### Outcome measures

The primary end point was comparison of forced expiratory volume in the first second. Safety, quality of life, and treatment satisfaction/preference were also compared between devices.

### Main results

Lung function was equivalent between nebulizers. Most domain scores from the Cystic Fibrosis Questionnaire-Revised and Treatment Satisfaction Questionnaire for Medication instruments were similar but patients strongly preferred the eRapid. Mean patient-reported administration times were shorter with the eRapid vs the LC Plus (2.7 vs 10.2min). Adverse events were similar between devices.

### Authors' conclusions

Administration of dornase alfa via the eRapid nebulizer resulted in comparable efficacy and safety, shorter nebulization times, and higher patient preference.

<http://dx.doi.org/10.1016/j.jcf.2015.04.003>

### See also

J Cyst Fibros. 2015 Nov;14(6):777-83. doi: 10.1016/j.jcf.2015.04.003. Epub 2015 Apr 25.

### Keywords

Deoxyribonuclease; Airway clearance drugs -expectorants- mucolytic- mucociliary-; Inhalation OR nebulised; pharmacological\_intervention; eRapid; nebuliser; non pharmacological intervention - devices OR physiotherapy; Respiratory System Agents; Dornase alpha; Pulmozyme; Pari;